The model's full reasoning — Q4 2023 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了一个已经部分开始贡献的新业务活动,并且报告期只捕获了其中一部分,而更完整的运行率将在未来几个季度到来,这是时间问题而非赢得问题。 检查记录中是否有这样的描述。管理层提到了几个业务活动,如养老金风险转移(PRT)、结构化结算、长寿再保险等。但需要找到具体的新贡献者,已经启动,且报告期只包含部分。 在RIS部分,提到“Volume growth in RIS away from PRT was very strong, with more than $5 billion of longevity, reinsurance sales and more than $3 billion of structured settlements.” 但这是全年数据,不是部分。 在亚洲,提到“Sales growth in Asia remained strong, propelled by market demand in Japan for FX denominated life insurance products and a new cash value life product in Korea.” 但这是销售增长,不是新贡献者部分启动。 在集团福利,提到“We're still in the midst of it, but initial indications in terms of our sales growth are in the 5% to 10% again year-over-year” 但这是销售,不是新贡献者。 在VII部分,提到“We expect PE and real estate returns will remain pressured in the first quarter of 2024 before trending higher.” 但这是投资回报,不是新业务。 在资本管理方面,提到“we have repurchased roughly $0.5 billion of MET common shares in the month of January.” 但这是回购,不是新业务。 在再保险交易方面,提到“the execution of our $19 billion risk transfer transaction that closed in November. This will free up more than $3 billion of capital over time” 但这是资本释放,不是新业务贡献。 在集团福利的展望中,提到“we are reducing our near-term group life mortality ratio and non-medical health interest adjusted benefit ratio ranges by 1 percentage point” 但这是比率调整,不是新业务。 在RIS部分,提到“we expect the investment spread range for 2024 is 115 to 140 basis points.” 但这是展望。 在MetLife Holdings,提到“we are lowering the adjusted earnings guidance range to $700 million to $900 million in 2024 to reflect the foregone earnings from the reinsurance transaction” 但这是下降。 在亚洲,提到“we expect adjusted earnings to grow roughly 20% in 2024 as we assume VII to have a greater impact throughout the year.” 但这是假设。 在EMEA,提到“we project EMEA’s adjusted earnings run rate to be roughly $60 million to $65 million per quarter in 2024” 但这是展望。 似乎没有明确描述一个已经启动的新业务,其报告期只包含部分,且未来几个季度将完全贡献。管理层提到了一些业务增长,但都是整体趋势,没有具体到某个新合同或新项目。 在回答中,管理层提到“we have repurchased shares totaling approximately $500 million in January.” 但这是回购,不是新业务。 在再保险交易中,提到“the reinsurance transaction that closed in November” 但这是交易,不是新业务贡献。 在集团福利中,提到“we are reducing our near-term group life mortality ratio” 但这是比率。 在RIS中,提到“we expect the investment spread range for 2024 is 115 to 140 basis points.” 但这是展望。 在亚洲,提到“we expect adjusted earnings to grow roughly 20% in 2024” 但这是展望。 在EMEA,提到“we project EMEA’s adjusted earnings run rate to be roughly $60
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| WHF | WhiteHorse Finance | Q1 2022 | 2022-05-10 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| ACHC | Acadia Healthcare Company, Inc. | Q4 2017 | 2018-02-22 | C+ |
| HTLF | Heartland Financial USA, Inc. | Q3 2017 | 2017-10-30 | B+ |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| LEA | Lear Corporation | Q2 2017 | 2017-07-26 | B+ |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| SHOO | Steven Madden, Ltd. | Q1 2017 | 2017-04-21 | C |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| WTS | Watts Water Technologies, Inc. | Q4 2016 | 2017-02-10 | B |
SHOO · Q1 2017 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes the Schwartz & Benjamin acquisition as a new contributor that began delivering sales in the reported Q1 period ($14 million, slightly above plan), with the results capturing only its early partial slice. Management explicitly notes that the full-quarter impact will arrive in subsequent quarters (dragging gross margin more going forward), 2017 will be breakeven-to-EPS, and meaningful profit contribution starts in 2018—making the fuller run-rate a pure timing matter of integration and ramp rather than any further winning. This meets all three criteria. (Madden NYC and SM Europe are also new launches/JVs with early/modest contributions and growth ahead, but Schwartz & Benjamin is the clearest fit for the exact timing story.) NO for the other items because they are either not yet live (China JV), not described as partial/early-slice (SM Europe international growth), or not framed as timing-driven ramp (Madden NYC modest contribution is positive but 2018+ profit is more about execution than pure timing). The answer is YES.
AFL · Q2 2023 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes the WINGS cancer insurance product launch in Japan Post (early April, during Q2) as a new, nameable contributor that began transacting mid-period. Management explicitly states it was the "majority contributor" to the 60% cancer sales increase in Q2 versus 2022, 26.6% overall sales premium growth, and notes the reported results captured only an early slice because "right when you launch the product, you'll have an immediate jump in sales in the early months followed by a calming down" with "still much more runway...
PDCO · Q3 2017 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes Heartland Dental as a new customer relationship that began contributing in January (during the reported Q3 period), with the rollout completed on schedule and the business now "getting close to being fully operational." Management explicitly notes that this was "not a significant contributor to consumable sales in the third quarter" — confirming the reported results captured only a partial, early slice — while highlighting the "outstanding start" and excitement for further growth as the relationship scales.